MoonLake Immunotherapeutics·4

Mar 3, 9:07 PM ET

Reich Kristian 4

4 · MoonLake Immunotherapeutics · Filed Mar 3, 2025

Insider Transaction Report

Form 4
Period: 2025-02-27
Reich Kristian
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-02-27+139,273139,273 total
    Exercise: $41.77Exp: 2035-02-27Class A ordinary shares, par value $0.0001 per share (139,273 underlying)
Footnotes (1)
  • [F1]This option represents a right to purchase a total of 139,273 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary